Faes Farma, S.A. · BME:FAE

Faes Farma — Investor Presentation (December 2023)

13 slides from Faes Farma's investor presentation, December 2023

  1. Slide 1: Faes Farma - Cuidando el hoy y el mañana

    a) FAES FARMA Cuidando el hoy y el manana at

  2. Slide 2: Excellence, Quality, Endeavour

    Founded in 1933, FAES FARMA develops, manufactures and commercializes EXCELLENCE pharmaceutical products and APIs, with a Results wide-ranging international projection 486M€ revenue QUALITY 124M€ EBITDA +6% vs. 2021 Today, FAES FARMA, the company that Global Company & began more than 90 years ago in

  3. Slide 3: Values, Mission and Vision

    EXCELLENCE QUALITY & VALUES MISSION VISION ENDEAVOUR Caring for health today to build a We are committed to finding innovative, To become a global healthcare healthier society honest, high-quality company that sets tomorrow solutions the benchmark for for integral care of reliability, quality, healt

  4. Slide 4: Financial Results: Total Income

    FINANCIAL RESULTS TOTAL INCOME 462 429 10 year CAGR 418 390 +10% 346 288 237 214 189 192 198 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total Income, M€

  5. Slide 5: Countries: Manufacturing Plants and Presence

    DERIO > 130 Basque Country, Spain New manufacturing plant (2023) Manufacture of FDF COUNTRIES DIRECT PRESENCE & AFFILIATES LAMIAKO in EU, LATAM and Basque Country, Spain AFRICA Industrial & RD Manufacture of API Manufacture of FDF MANUFACTURING PLANTS FAES & PARTNERS MADRID Spain Commercial headquar

  6. Slide 6: Commercial Presence

    COMMERCIAL PRESENCE > 130 B2C Direct presence (Iberia, LATAM, Africa) COUNTRIES B2B Partners and Exports Faes IBERIA DIRECT PRESENCE & AFFILIATES in EU, LATAM and AFRICA MANUFACTURING Faes LATAM PLANTS Faes MEA FAES & PARTNERS

  7. Slide 7: Licensing Opportunities: Strategic Therapeutic Areas

    COLLABORATION MODELS LICENSING OPPORTUNITIES STRATEGIC THERAPEUTIC AREAS

  8. Slide 8: Licensing Opportunities: Other Molecules

    COLLABORATION MODELS LICENSING OPPORTUNITIES OTHER MOLECULES

  9. Slide 9: Licensing Opportunities: Generics

    COLLABORATION MODELS MOLECULE DOSE / FORM LICENSING OPPORTUNITIES 1G tabs METFORMIN 500 mg tabs 850 mg tabs GENERICS SITAGLIPTIN 100 mg tabs MOLECULE DOSE / FORM METFORMIN SITAGLIPTIN 1G / 50 mg tabs 100mg tabs ALLOPURINOL DIOSMIN / HESPERIDIN 450 mg / 50 mg tabs 300 mg tabs CIPROFLOXACIN 500 mg tab

  10. Slide 10: Licensing Opportunities: Over-the-Counter

    COLLABORATION MODELS LICENSING OPPORTUNITIES OVER-THE-COUNTER Pankreoflat® prescription Double action on digestive disorders involving aerophagia, 50 Coated Pancreatin 172mg / flatulence, stomach heaviness & slow digestion. gastro-resistant tablets Dimethicone 80mg Drugs Non- Actimag® For the preven

  11. Slide 11: Other Opportunities: Over-the-Counter Supplements and Devices

    COLLABORATION MODELS OTHER OPPORTUNITIES OVER-THE-COUNTER Arcid® Offers rapid relief of heartburn and reflux symptoms, Mint-vanilla flavour Calcium Carbonate, Sodium Bicarbonate, protection and regeneration of the mucosa 12 sticks Galactomannan, Malva sylvestris & Hyaluronic Acid 24 sticks Medical D

  12. Slide 12: Commercial Presence: Worldwide Strategic Partners B2B

    COMMERCIAL PRESENCE PARTNERS - B2B Worldwide strategic partners

  13. Slide 13: Faes Farma - Cuidando el hoy y el mañana

    a) FAES FARMA Cuidando el hoy y el manana at

Faes Farma — Investor Presentation (December 2023) on 6ix